CUTISS is making steady progress in the clinical development of denovoSkin™, its personalized, bio-engineered skin graft, as part of the ongoing Phase 3 clinical trial for the treatment of severe burns.
The first enrolled patients have now been successfully grafted with denovoSkin™ at clinical sites in the Netherlands and Spain, with additional recruitment underway in France and Italy. There are eight sites involved in this confirmatory study in the EU.
In parallel, the trial has also been approved in Switzerland by Swissmedic, with preparations in place to begin patient recruitment.
We thank the clinical teams, surgeons, patients, collaborators, and stakeholders whose work and dedication is driving this important progress.
